janet
englund
tobia
feuchting
per
ljungman
virus
caus
acut
respiratori
ill
gener
popul
respons
hospit
person
age
underli
medic
condit
also
common
caus
respiratori
diseas
transplant
recipi
widespread
avail
sensit
reliabl
molecular
detect
method
common
respiratori
virus
includ
respiratori
syncyti
viru
rsv
influenza
parainfluenza
virus
piv
adenovirus
rhinovirus
rhv
coronavirus
detect
worldwid
transplant
recipi
recent
newli
identifi
virus
human
metapneumovirus
hmpv
new
strain
coronavirus
bocaviru
also
detect
symptomat
transplant
recipi
communityacquir
respiratori
virus
crv
signific
impact
morbid
mortal
transplant
recipi
caus
varieti
diseas
rang
selflimit
upper
respiratori
tract
ill
uri
lifethreaten
lower
respiratori
tract
infect
lrti
occasion
dissemin
diseas
diseas
manifest
depend
specif
viru
type
transplant
type
degre
durat
immun
defici
pneumonia
follow
infect
virus
may
primarili
viral
bacteri
fungal
mix
origin
respiratori
virus
parainfluenza
virus
may
also
higher
associ
rate
copathogen
nosocomi
transmiss
crv
common
widespread
hospit
outbreak
crv
occur
sometim
devast
sequela
virus
easili
transmit
person
person
inpati
outpati
set
infect
control
measur
enforc
measur
critic
control
spread
infect
commun
outbreak
rsv
infect
typic
occur
late
fall
winter
earli
spring
frequent
follow
outbreak
human
metapneumoviru
influenza
outbreak
typic
occur
winter
temper
climat
may
occur
throughout
year
tropic
area
parainfluenza
viru
infect
occur
throughout
year
outbreak
occur
primarili
spring
summer
fall
virus
rhinovirus
coronavirus
adenovirus
tend
take
place
throughout
year
although
sporad
outbreak
respiratori
virus
may
occur
prompt
accur
identif
respiratori
viral
pathogen
critic
import
transplant
recipi
enabl
specif
infect
control
precaut
institut
initi
specif
antivir
therapi
potenti
delay
immunosuppress
therapi
transplant
appropri
collect
specimen
critic
import
success
identif
virus
clinic
sampl
differ
diagnost
method
use
recent
year
use
multiplex
pcr
techniqu
gain
popular
method
may
detect
multipl
respiratori
virus
singl
readili
obtain
specimen
manag
crv
infect
controversi
except
influenza
infect
neuramidas
inhibitor
shown
effect
establish
treatment
sever
uncontrol
studi
perform
ribavirin
suggest
efficaci
least
prevent
progress
lower
tract
diseas
although
licens
proven
therapi
parainfluenza
viru
infect
ribavirin
antivir
effect
parainfluenza
viru
cell
cultur
use
treatment
lower
respiratori
tract
diseas
immunocompromis
host
case
report
document
decreas
viral
load
clinic
improv
sever
children
sever
combin
immunodefici
parainfluenza
viru
infect
follow
multipl
treatment
aerosol
ribavirin
laboratori
data
support
antivir
activ
oseltamivir
parainfluenza
virus
although
new
parainfluenzaspecif
antivir
agent
activ
neuraminidas
parainfluenza
virsu
develop
preliminari
data
indic
infect
human
bocaviru
human
coronaviru
newli
identifi
virus
wuki
virus
less
like
caus
sever
problem
transplant
patient
compar
welldescrib
viral
pathogen
adenovirus
adv
nonenvelop
lytic
dna
virus
fiftytwo
differ
human
serotyp
identifi
divid
subgroup
speci
immunocompromis
patient
adv
caus
lethal
diseas
damag
occur
mani
differ
organ
last
decad
adv
infect
context
allogen
hematopoiet
stem
cell
transplant
hsct
increasingli
recogn
caus
transplantrel
mortal
trm
especi
children
sever
immunocompromis
adult
undergo
haploident
celldeplet
transplant
rund
et
al
report
significantli
higher
incid
advinfect
patient
receiv
antithymocyt
globulin
atg
studi
van
tol
et
al
found
risk
adv
infect
diseas
increas
patient
intens
cell
deplet
also
demonstr
patient
delay
cell
recoveri
significantli
higher
risk
adv
infect
diseas
studi
found
strong
correl
presenc
advspecif
cell
clearanc
adv
infect
feuchting
et
al
show
patient
advspecif
cell
could
found
higher
number
patient
clear
adv
infect
compar
myer
et
al
found
delay
recoveri
advspecif
cell
recipi
unrel
haploident
graft
correl
increas
risk
adv
diseas
observ
outcom
adv
diseas
relat
specif
immun
reconstitut
suggest
recoveri
advspecif
immun
critic
process
improv
decreas
intens
immunosuppress
addit
transfer
virusspecif
cell
shown
effect
control
cytomegaloviru
cmv
epsteinbarr
viru
ebv
infect
hsct
recipi
although
differ
adv
subtyp
extent
antigen
distinct
subtyp
share
cell
epitop
hexon
protein
furthermor
crossreact
shown
ex
vivo
earli
vitro
experi
show
advspecif
cell
gener
adv
puls
dendrit
cell
lyse
adenoinfect
cell
chatziandr
et
al
feuchting
et
al
isol
advspecif
cell
interferon
inf
gsecret
captur
assay
could
show
specif
antigen
respons
cell
upon
restimul
differ
adv
strain
anoth
promis
approach
adopt
immunotherapi
allodeplet
donor
cell
improv
immun
reconstitut
concern
common
virus
pilot
studi
feuchting
et
al
treat
patient
advviremia
virusspecif
donor
cell
gener
infg
secret
assay
evalu
patient
receiv
adopt
cell
transfer
infus
cell
underw
vivo
expans
viral
load
decreas
peripher
blood
vivo
expans
specif
cell
doseindepend
suggest
even
low
number
advspecif
donor
cell
expand
easili
vivo
presenc
viremia
mortal
rate
follow
influenza
infect
hsct
recipi
previous
report
around
although
recent
data
report
outcom
widespread
util
neuramidas
inhibitor
suggest
somewhat
lower
risk
fatal
outcom
recent
outbreak
new
pandem
strain
stress
import
strategi
place
manag
patient
influenza
infect
control
differ
part
immun
system
includ
innat
adapt
immun
system
vaccin
cell
b
cell
respons
activ
clearanc
primari
infect
depend
cell
cell
recogn
epitop
hemagglutinin
ha
intern
protein
influenza
viru
follow
recoveri
influenza
antigenspecif
cell
maintain
longlast
immunolog
memori
respond
quickli
restimul
b
cell
produc
antibodi
influenza
protein
haspecif
antibodi
appear
within
week
infect
contrast
antibodi
direct
ha
antibodi
direct
na
neutral
viru
reduc
releas
viru
infect
cell
problem
specif
influenza
virus
antigen
shift
drift
circul
influenza
viru
regularli
occur
requir
adapt
season
trival
influenza
vaccin
must
administ
provid
protect
two
main
type
influenza
vaccin
exist
inactiv
live
coldadapt
vaccin
intranas
administr
safeti
efficaci
intranas
live
vaccin
evalu
hsct
recipi
safe
hivinfect
adult
children
influenza
infect
occur
earli
hsct
might
result
sever
diseas
would
logic
immun
candid
hsct
howev
studi
show
adult
patient
hematolog
malign
respond
poorli
vaccin
addit
likelihood
whatev
immun
exist
lost
high
time
hsct
import
vaccin
respons
engelhard
et
al
studi
antibodi
respons
dose
influenza
viru
vaccin
given
month
hsct
allogen
bmt
recipi
adult
children
receiv
celldeplet
transplant
show
signific
associ
serolog
respons
interv
bone
marrow
transplant
bmt
vaccin
second
vaccin
dose
margin
effect
pauksen
et
al
found
respons
rate
allogen
sct
patient
vaccin
month
hct
influenza
b
howev
despit
suboptim
serolog
respons
clinic
effect
vaccin
could
potenti
exist
machado
et
al
found
influenza
vaccin
perform
least
month
sct
efficaci
prevent
influenza
possibl
protect
mediat
also
cell
avetisyan
et
al
analyz
cell
respons
adult
patient
found
signific
increas
number
ifng
produc
cell
patient
vaccin
month
hct
vaccin
later
although
respons
late
group
stronger
furthermor
shown
elderli
risk
influenza
diseas
compar
individu
demonstr
cellmedi
respons
alon
antibodi
respons
alon
type
respons
respons
vaccin
suboptim
earli
transplant
also
autolog
hsct
recipi
specif
data
exist
regard
vaccin
efficaci
patient
receiv
rituximab
close
proxim
transplant
either
pretranspl
chemotherapi
part
condit
regimen
hsct
howev
nontranspl
patient
immun
respons
within
month
receiv
monoclon
antibodi
poor
therefor
like
case
also
autolog
hsct
new
pandem
strain
spread
rapidli
around
world
new
vaccin
rapidli
develop
uncertainti
regard
efficaci
safeti
vaccin
especi
includ
new
adjuv
preliminari
data
suggest
dose
vaccin
safe
abl
induc
immun
respons
addit
develop
antivir
resist
neuraminidas
inhibitor
demonstr
immunocompromis
host
although
spread
resist
viru
document
lifelong
season
influenza
vaccin
inactiv
influenza
vaccin
recommend
hsct
recipi
unknown
earli
vaccin
hct
benefici
influenza
vaccin
safe
current
recommend
start
month
hsct
influenza
vaccin
famili
member
household
contact
strongli
recommend
influenza
season
limit
risk
influenza
exposur
hct
candid
recipi
season
influenza
vaccin
also
strongli
recommend
health
care
worker
deal
hct
recipi
although
sever
fatal
measl
report
hsct
recipi
risk
seriou
infect
allogen
hsct
like
low
howev
patient
undergo
transplant
reduc
intens
condit
ric
regimen
pregnanc
potenti
patient
like
increas
therebi
risk
congenit
rubella
syndrom
avail
mmr
vaccin
live
attenu
vaccin
recommend
use
immunocompromis
patient
immun
consid
allogen
hsct
patient
without
chronic
graftversushost
diseas
cgvhd
ongo
immunosuppress
data
indic
measl
vaccin
given
patient
without
sever
advers
effect
year
sct
epidem
brazil
patient
safe
immun
year
sct
although
data
limit
varicella
vaccin
might
consid
seroneg
hct
recipi
meet
criteria
live
viru
vaccin
delin
measl
vaccin
zoster
vaccin
use
two
new
inactiv
varicella
vaccin
develop
data
regard
vaccin
hsct
recipi
recent
licens
vaccin
human
papilloma
viru
vaccin
yet
recommend
new
cmv
vaccin
develop
phase
ii
data
show
promis
immunogen
viral
infect
immunocompromis
host
abil
caus
sever
diseas
much
higher
rate
healthi
popul
care
attent
viral
epidemiolog
viral
outbreak
commun
diagnost
screen
symptomat
patient
onset
new
respiratori
symptom
use
care
infect
control
method
rigor
enforc
outpati
inpati
set
import
limit
viral
spread
high
risk
patient
use
antivir
therapi
prior
develop
respiratori
failur
may
also
benefit
patient
efficaci
immunoglobulin
product
monoclon
antibodi
product
limit
spread
infect
within
individu
patient
frequent
util
yet
proven
rigor
trial
patient
popul
clinic
studi
agent
prevent
treat
import
viral
infect
urgent
need
financi
disclosur
dr
englund
receiv
grant
support
nih
remain
author
noth
disclos
